Updates in the Management of CIDP: The Pharmacist's Role in Individualizing Care, featuring a Patient Perspective

This activity features a Patient Perspective interview.

Program Description

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disorder that affects the peripheral nervous system and can lead to sensory impairment or disease-related disability. The treatment for CIDP centers on decreasing clinical burden and reducing symptoms so patients may retain functional ability. Immunoglobulin (Ig) is frequently selected as initial therapy for patients with CIDP and is available in intravenous (IV) and subcutaneous (SC) formulations. This activity will review administration implications and dosing considerations specific to IVIg and SCIg formulations for specialty pharmacists and patients. Expert panelists will share perspectives and clinical experiences in individualizing therapy to ensure patient safety as well as best practices in switching IVIg to SCIg therapy. A patient perspective interview incorporated throughout the program will highlight the experience of an individual living with CIDP, including discussion of challenges surrounding diagnosis and access to treatment.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: August 9, 2022
Expiration date: October 9, 2022

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Express the clinical burden of chronic inflammatory demyelinating polyneuropathy (CIDP) to effectively incorporate current treatment strategies and emerging therapeutic approaches
• Identify place in therapy and best practices for transition of intravenous immunoglobulin to subcutaneous immunoglobulin among patients with CIDP
• Investigate new and emerging treatment options for CIDP based on the latest safety and efficacy data, relevant clinical evidence, and individualized needs of the patient
• Explain aspects of care in which pharmacists can be involved to optimize outcomes for patients with CIDP

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-324-L01-P. The activity is available for CE credit through October 9, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Amy E. Clarke, BSN, RN, IgCN; Karissa L. Gable, MD, Erica Marini, PharmD, MS, BCPS; have no relevant financial relationships with commercial interests to disclose.

James L. Sheets, PharmD, IgCP, has the following relevant financial relationships with commercial interests to disclose:

Advisory Board: Koru Pharma, Evolve Biologics

Kelsey Giara, PharmD; has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms